Immuneoncia Therapeutics
Seongnam
About Immuneoncia Therapeutics
ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 is in Phase 1 clinical trial. Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with Janssen (Belgium), the Clorox Company (USA), and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $60.6M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2022)
- Website: immuneoncia.com
- Phone: +82 (31) 306-8186
Industries & Categories
Biotechnology, Medical, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/immuneoncia-therapeutics-161563 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.